{
    "nctId": "NCT04665921",
    "briefTitle": "A Study of SGN-STNV in Advanced Solid Tumors",
    "officialTitle": "A Phase 1 Study of SGN-STNV in Advanced Solid Tumors",
    "overallStatus": "TERMINATED",
    "conditions": "Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 111,
    "primaryOutcomeMeasure": "Incidence of adverse events (AEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Disease indication\n\n  * Must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies and should have no appropriate standard-of-care therapeutic option.\n\n    * Non-small cell lung cancer (NSCLC)\n    * HER2 negative breast cancer\n    * Ovarian cancer\n    * Cervical cancer\n    * Endometrial cancer\n    * Esophageal cancer\n    * Gastric cancer and GEJ carcinoma\n    * Colorectal cancer\n    * Exocrine pancreatic adenocarcinoma\n    * Appendiceal adenocarcinoma and pseudomyxoma peritonei of unknown origin\n* Participants enrolled in the following study parts should have an appropriate tumor site that satisfies the following criteria:\n\n  * Site has tumor that is not a target lesion and has not been previously irradiated (unless progression has occurred since end of radiotherapy)\n  * Site has tumor that is accessible for a minimally invasive biopsy that does not present a significant risk, AND\n  * Participant must agree to a biopsy as follows\n\n    * Disease-specific expansion cohorts: pre-treatment biopsy, unless medically infeasible following consultation with the medical monitor\n    * Biology expansion cohort: pretreatment biopsy (required) and additional on-treatment biopsy during Cycle 1 (unless medically infeasible following consultation with the medical monitor)\n* Measurable disease per the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) at baseline\n* An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Adequate renal, hepatic, and hematologic function\n\nExclusion Criteria\n\n* History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.\n* Known active central nervous system metastases\n* Carcinomatous meningitis\n* Previous receipt of monomethylauristatin E (MMAE)-containing drugs\n* Pre-existing neuropathy \u2265 Grade 2 per the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0\n* Any uncontrolled \u2265 Grade 3 (per the NCI CTCAE, Version 5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of SGN-STNV\n\nThere are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}